Author

Eric Bragg

Observed institution: Amgen (United States)

OpenAlex ID: A5016906830

Molecular basis for the loss-of-function effects of the Alzheimer's disease–associated R47H variant of the immune receptor TREM2

2018 · Athena Sudom, Santosh Talreja, et al. · Journal of Biological Chemistry · 147

Abstract 933: ProTriTAC is a modular and robust T cell engager prodrug platform with therapeutic index expansion observed across multiple tumor targets

2021 · S. Jack Lin, Sony S. Rocha, et al. · Cancer Research · 11

Abstract 2928: TROP2 ProTriTAC™, a protease-activated T cell engager prodrug targeting TROP2 for the treatment of solid tumors

2023 · Sony S. Rocha, Regina Lin, et al. · Cancer Research · 7

867 TriTAC-XR is an extended-release T cell engager platform designed to minimize cytokine release syndrome by reducing Cmax in systemic circulation

2021 · Kathryn Kwant, Sony Rocha, et al. · Journal for ImmunoTherapy of Cancer · 7

Abstract 2927: ITGB6 ProTriTAC™, a protease-activated T cell engager prodrug targeting Integrin-β6 for the treatment of solid tumors

2023 · Regina J. Lin, Sony S. Rocha, et al. · Cancer Research · 2

Abstract 2861: TriTAC-XR: An extended-release T cell engager platform designed to minimize cytokine release syndrome

2022 · Kathryn Strobel Kwant, Sony S. Rocha, et al. · Cancer Research · 1

Works count: 6

Citation count: 175

H-index: 4

I10-index: 2